INDENTURE dated as of December 11, 2014 by and between ZP SPV 1 K/S, a limited partnership organized under the laws of Denmark, as issuer of the Notes described herein, and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as initial...Indenture • June 16th, 2016 • Zealand Pharma a/S • Pharmaceutical preparations • New York
This INDENTURE, dated as of December 11, 2014, is by and between ZP SPV 1 K/S, a limited partnership organized under the laws of Denmark, as issuer of the Notes described herein, and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as initial trustee of the Notes described herein and as Operating Bank.
LICENSE AND COLLABORATON AGRFEMENT BETWEEN BOEHBINGER INGELHEIM INTERNATIONAL GMBH AND ZEALAND PHARMA A/S BI Contract No.: 43037553 CONFIDENTIALLicense and Collaboration Agreement • June 16th, 2016 • Zealand Pharma a/S • Pharmaceutical preparations
This License and Collaboration Agreement (the “Agreement”) effective as of 15 June 2011 (the “Effective Date”) is entered into by and between Zealand Pharma A/S (“Zealand Pharma”), Smedeland 36, 2600 Glostrup, Denmark (VAT-ID No: DK 20 04 50 78) and Boehringer Ingelheim International GmbH (“BI”), Binger Strasse 173 55216 Ingelheim am Rhein, Germany (VAT-ID No: DE 811138149). Zealand Pharma and BI may hereinafter also be referred to individually as a “Party” or collectively as the “Parties.”
LICENSE AGREEMENT by and between Zealand Pharma A/S and Aventis Pharma Deutschland GmbH Execution VersionLicense Agreement • June 16th, 2016 • Zealand Pharma a/S • Pharmaceutical preparations
[***] Certain information in this document has been omitted and submitted separately to the Securities and Exchange Commission. Confidential treatment has been requested separately with respect to the omitted portions.
LICENSE AGREEMENT BETWEEN ZEALAND PHARMA A/S AND HELSINN HEALTHCARE SALicense Agreement • June 16th, 2016 • Zealand Pharma a/S • Pharmaceutical preparations • England and Wales
[***] Certain information in this document has been omitted and submitted separately to the Securities and Exchange Commission. Confidential treatment has been requested separately with respect to the omitted portions.
